Like one of the traction cities out of Mortal Engines, Stryker (SYK)
continues to roll along, executing well with its core businesses, but
also eagerly gobbling up technologies and product portfolios that
management believes can aid its long-term growth prospects. While the
third quarter wasn’t perfect down the line and the Wright Medical (WMGI) deal isn’t without some risk, Stryker rolls into 2020 with a lot of momentum and healthy prospects across its business.
As
perhaps the best med-tech company out there now, Stryker continues to
command a premium valuation. While a company with this combination of
growth, organic growth, and margin power should be highly valued, I
believe market outperformance increasingly relies on multiple expansion
that seems less likely to me.
Read more here:
Stryker Continues To Cut A Swath Through Med-Tech
No comments:
Post a Comment